| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-05-14 | RedXPharma (UK) Redx Immunology (UK) | Redx Immunology | establishment of a new subsidiary in the EU |
Autoimmune diseases - Immunological diseases - Cancer - Oncology | Establishment of a new subsidiary in the EU | |
| 2015-05-13 | Abbott (USA - IL) AstraZeneca (UK | companion diagnostic tests for tralokinumab | asthma | development |
Allergic diseases - Inflammatory diseases - Respiratory diseases | Development agreement |
| 2015-05-12 | Juventas Therapeutics (USA - OH) | nomination |
Cardiovascular diseases | Nomination | ||
| 2015-05-12 | AOP Orphan Pharmaceuticals (Austria) Cardiome Pharma (Canada) | Esmocard® and Esmocard Lyo® (esmolol hydrochloride) | supraventricular tachycardia (except for pre-excitation syndromes), rapid control of the ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short-acting agent is desirable, tachycardia and hypertension occurring in the perioperative phase and non-compensatory sinus tachycardia where, in the physician\'s judgement the rapid heart rate requires specific intervention | commercialisation |
Cardiovascular diseases | Commercialisation agreement |
| 2015-05-12 | Dyax (USA - MA) | nomination |
Nomination | |||
| 2015-05-12 | Baxter (USA - IL) Baxalta (USA - IL) Sigma-Tau Finanziaria (Italy) | Oncaspar® (pegaspargase), calaspargase pegol | acute lymphoblastic leukemia (ALL) | product acquisition | Cancer - Oncology - Rare diseases | Product acquisition |
| 2015-05-12 | Adaptimmune (UK) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-05-12 | Elidera, Moderna Therapeutics' venture (USA - MA) | nomination |
Rare diseases | Nomination | ||
| 2015-05-12 | Prima Biomed (Australia) Sydys Corporation (USA - WA) | CVac™ immuno?oncology program | licensing |
Cancer - Oncology | Licensing agreement | |
| 2015-05-11 | Astellas (Japan) Potenza Therapeutics (USA - MA) | programs with novel mechanisms of action targeting immune checkpoint pathways, co-stimulatory signals and regulatory T cells | R&D |
Cancer - Oncology | R&D agreement | |
| 2015-05-11 | Sucampo Pharmaceuticals (USA - MD) Harbin Gloria Pharmaceuticals (China) | Amitiza® (lubiprostone) | chronic idiopathic constipation (CIC) in adults, opioid-induced constipation (OIC) in adults with chronic, non-cancer pain | licensing development commercialisation |
Digestive diseases | Licensing agreement |
| 2015-05-11 | Eli Lilly (USA - IN) BioNTech (Germany) | cancer immunotherapies | R&D |
Cancer - Oncology | R&D agreement | |
| 2015-05-11 | Theradiag (France) Somagen Diagnostics (Canada) | biotherapy monitoring range LISA TRACKER | distribution | Distribution agreement | ||
| 2015-05-11 | Arena Pharmaceuticals (USA - CA) Roivant Sciences (Bermuda - USA - NY) | nelotanserin | development marketing supply |
Mental diseases - Neurological diseases | Development agreement | |
| 2015-05-11 | Alexion Pharmaceuticals (USA - CT) | construction of new premises |
Rare diseases - Genetic diseases | Construction of new premises | ||
| 2015-05-11 | Ability Pharmaceuticals (Spain) SciClone Pharmaceuticals (USA - CA) | ABTL0812 (sodium 2-hydroxylinoleate) | licensing development commercialisation |
Cancer - Oncology | Licensing agreement | |
| 2015-05-11 | Ability Pharmaceuticals (Spain) SciClone Pharmaceuticals (USA - CA) | ABTL0812 (sodium 2-hydroxylinoleate) | licensing development commercialisation |
Cancer - Oncology | Licensing agreement | |
| 2015-05-11 | Ability Pharmaceuticals (Spain) SciClone Pharmaceuticals (USA - CA) | ABTL0812 (sodium 2-hydroxylinoleate) | licensing development commercialisation |
Cancer - Oncology | Licensing agreement | |
| 2015-05-11 | Ability Pharmaceuticals (Spain) SciClone Pharmaceuticals (USA - CA) | ABTL0812 (sodium 2-hydroxylinoleate) | licensing development commercialisation |
Cancer - Oncology | Licensing agreement | |
| 2015-05-11 | Ability Pharmaceuticals (Spain) SciClone Pharmaceuticals (USA - CA) | ABTL0812 (sodium 2-hydroxylinoleate) | licensing development commercialisation |
Cancer - Oncology | Licensing agreement |
